You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased.
By combining with ArcherDX, Invitae will gain tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response.
The San Francisco-based firm reported $64.2 million in revenues, up from $40.6 million a year ago and beating the average Wall Street estimate of $59.4 million.
The available data suggests PGx may be useful in managing medications for COVID-19 patients and in helping people struggling with the mental health impact of the pandemic.
Invitae will provide free genetic testing on a 53-gene panel and counseling to patients suspected of having an LSD to facilitate earlier diagnosis and appropriate treatment.
News items for the in vitro diagnostics industry for the week of April 6, 2020.
The company withdrew its 2020 revenue guidance and said it expects to report revenues of more than $63 million in the quarter ended March 31.
Of the 28 companies in the 360 Index, six companies' share prices increased while the share values of 22 declined month over month.
Invitae said YouScript and Genelex will enable it to provide pharmacogenomic testing, while Diploid will help interpret WGS results.
Of the 28 companies in the index, nine companies' share prices increased while the share values of 19 declined month over month.